Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$25 Mln
P/E Ratio
--
P/B Ratio
1.89
Industry P/E
--
Debt to Equity
0.23
ROE
-0.79 %
ROCE
-69.14 %
Div. Yield
0 %
Book Value
1.22
EPS
-1.51
CFO
$-42.58 Mln
EBITDA
$-53.78 Mln
Net Profit
$-71.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
CollPlant Biotechnologies - ADR
| -38.47 | -13.14 | -40.93 | -62.39 | -40.13 | -27.94 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
CollPlant Biotechnologies - ADR
| -23.47 | -48.96 | 51.90 | 88.95 | 35.71 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.43 | 138.40 | -- | -23.63 | |
| 2.18 | 109.01 | -- | -103.34 | |
| 0.96 | 23.99 | -- | -- | |
| 10.96 | 466.01 | -- | 342.83 |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The... company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in a variety of 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company also provides VergenixSTR, a soft tissue matrix, intended for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel, intended for the treatment of chronic and acute wounds. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. Address: Weizmann Science Park, Rehovot, Israel, 7670104 Read more
CEO & Director
Mr. Yehiel Tal
CEO & Director
Mr. Yehiel Tal
Headquarters
Rehovot
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CollPlant Biotechnologies Ltd - ADR stood at $ 19 Mln as on 31-Dec-24
The share price of CollPlant Biotechnologies Ltd - ADR is $2.22 (NASDAQ) as of 29-Apr-2025 14:29 EDT. CollPlant Biotechnologies Ltd - ADR has given a return of -40.13% in the last 3 years.
CollPlant Biotechnologies Ltd - ADR has a market capitalisation of $ 25 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of CollPlant Biotechnologies Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CollPlant Biotechnologies Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of CollPlant Biotechnologies Ltd - ADR.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in a variety of 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company also provides VergenixSTR, a soft tissue matrix, intended for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel, intended for the treatment of chronic and acute wounds. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. Address: Weizmann Science Park, Rehovot, Israel, 7670104
The CEO & director of Mr. Yehiel Tal. is CollPlant Biotechnologies Ltd - ADR, and CFO & Sr. VP is Mr. Yehiel Tal.
There is no promoter pledging in CollPlant Biotechnologies Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
48
|
|
|
15
|
|
|
8
|
|
|
2
|
| CollPlant Biotechnologies Ltd - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-79.46
|
|
Operating margin(%)
|
-3349.71
|
|
Net Margin(%)
|
-3225.05
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CollPlant Biotechnologies Ltd - ADR was $0 Mln.
$0.01
(
